HRP20171048T1 - Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe - Google Patents
Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe Download PDFInfo
- Publication number
- HRP20171048T1 HRP20171048T1 HRP20171048TT HRP20171048T HRP20171048T1 HR P20171048 T1 HRP20171048 T1 HR P20171048T1 HR P20171048T T HRP20171048T T HR P20171048TT HR P20171048 T HRP20171048 T HR P20171048T HR P20171048 T1 HRP20171048 T1 HR P20171048T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- peptide compound
- abu
- xaa1
- ala
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title claims 2
- 229940044601 receptor agonist Drugs 0.000 title claims 2
- 102000015427 Angiotensins Human genes 0.000 title 1
- 108010064733 Angiotensins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 150000001413 amino acids Chemical group 0.000 claims 9
- -1 aromatic amino acids Chemical class 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 108050008993 Angiotensin II receptor type 2 Proteins 0.000 claims 2
- 102000000469 Angiotensin II receptor type 2 Human genes 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101150116411 AGTR2 gene Proteins 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000015925 Proto-oncogene Mas Human genes 0.000 claims 1
- 108050004181 Proto-oncogene Mas Proteins 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000024389 cytopenia Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
Claims (15)
1. Ciklični peptidni spoj koje se sastoji od aminokiselinske sekvence Xaa1- Asp-Arg- Ile/Val- Xaa5- Ile/Val- His- Xaa8, koje sadrži vezu u vidu tioetarskog mosta između bočnih lanaca Xaa5 i Xaa8, tako da Xaa5 i Xaa8 zajedno čine strukturu prema bilo kojoj od općih formula:
[image]
[image]
[image]
naznačeno time što su R, R1, R2, R3, R4 i R5 nezavisno odabrani od -H, C1-C10 alkil ili aralkil grupe, pri čemu su poželjno R, R1, R2, R3, R4 i R5 nezavisno odabrani od H i CH3, i pri čemu je Xaa1 izabran iz grupe koja se sastoji od naelektriziranih aminokiselina, aromatičnih aminokiselina i hidrofobnih aminokiselina i njihovih varijanti otpornih na proteazu,
ili njegova farmaceutski prihvatljiva sol.
2. Peptidni spoj prema patentnom zahtjevu 1, naznačeno time što je Xaa1 izabran iz grupe koja se sastoji od D-stereoizomera naelektrisanih aminokiselina, aromatičnih aminokiselina i hidrofobnih aminokiselina.
3. Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 pozitivno naelektrizirana aminokiselina, pri čemu poželjno Xaa1 predstavlja Lys ili Arg.
4. Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 negativno naelektrizirana aminokiselina, pri čemu poželjno Xaa1 predstavlja Asp, Glu ili pyroGlu.
5. Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 hidrofobna aminokiselina, pri čemu poželjno Xaa1 predstavlja Ile, Leu ili Val.
6. Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 aromatična aminokiselina, pri čemu poželjno Xaa1 predstavlja Tyr ili Phe.
7. Peptidni spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što Xaa5 predstavlja D-stereoizomer.
8. Peptidni spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što Xaa8 predstavlja L- stereoizomer.
9. Peptidni spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što Xaa5 predstavlja D-stereoizomer i Xaa8 predstavlja L- stereoizomer.
10. Peptidni spoj prema bilo kojem od prethodnih patentnih zahtjeva, koje ima aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od:
Lys-Asp-Arg-Val-Abu/Ala-Ile-His-Abu/Ala (K-cAng(1-7))
Asp-Asp-Arg-Val-Abu/Ala-Ile-His-Abu/Ala (D-cAng(1-7))
Tyr-Asp-Arg-Val-Abu/Ala-Ile-His-Abu/Ala (Y-cAng(1-7))
Ile-Asp-Arg-Val-Abu/Ala-Ile-His-Abu/Ala (I-cAng(1-7))
Asn-Asp-Arg-Val-Abu/Ala-Ile-His-Abu/Ala (N-cAng(1-7))
pod uvjetom da peptid ne sadrži dva Abu (2-aminobuterna kiselina) ostatka.
11. Farmaceutska kompozicija koja sadrži peptidni spoj prema bilo kojem od patentnih zahtjeva 1 do 10, i farmaceutski prihvatljiv adjuvans, razblaživač ili nosač.
12. In vitro upotreba peptidnog jedinjenja prema bilo kom od patentnih zahtjeva 1 do 10 kao agonista angiotenzin II receptora tipa 2 (AT2).
13. Peptidni spoj prema bilo kom od patentnih zahtjeva 1 do 10, za upotrebu u liječenju i/ili prevenciji stanja u kome je selektivni agonizam prema AT2 receptoru poželjan i/ili potreban.
14. Peptidni spoj prema bilo kojem od patentnih zahtjeva 1 do 10, za upotrebu u liječenju i/ili prevenciji prema patentnom zahtjevu 13, naznačeno time što je navedeno stanje dijabetes (tipa II), kardiovaskularno oboljenje, hipertenzija, srčana insuficijencija, infekcija, alopecija, anemija, citopenija, oboljenje živaca, inflamacija, fibroza, kancer, akutni respiratorni distres sindrom ili zarastanje rana.
15. Kombinirani proizvod koji sadrži kao zasebne entitete (A) peptidni spoj prema bilo kojem od patentnih zahtjeva 1-10; i (B) spoj odabran od antagonista AT1 receptora i ACE inhibitora, i/ili (C) spoj odabran od agonista Mas receptora i ACE2, naznačen time što je svaka od komponenti (A), (B) i/ili (C) formulirana u smjesi sa farmaceutski prihvatljivim adjuvansom, razblaživačem ili nosačem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10192208A EP2455388A1 (en) | 2010-11-23 | 2010-11-23 | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
| EP11791636.1A EP2643342B1 (en) | 2010-11-23 | 2011-11-22 | Novel angiotensin type 2 (at2) receptor agonists and uses thereof |
| PCT/NL2011/050793 WO2012070936A1 (en) | 2010-11-23 | 2011-11-22 | Novel angiotensin type 2 (at2) receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171048T1 true HRP20171048T1 (hr) | 2017-10-06 |
Family
ID=44072497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171048TT HRP20171048T1 (hr) | 2010-11-23 | 2017-07-10 | Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9290540B2 (hr) |
| EP (2) | EP2455388A1 (hr) |
| JP (2) | JP5837087B2 (hr) |
| KR (1) | KR101512916B1 (hr) |
| CN (1) | CN103314006B (hr) |
| AU (1) | AU2011332397B2 (hr) |
| CA (1) | CA2818299C (hr) |
| CY (1) | CY1119036T1 (hr) |
| DK (1) | DK2643342T3 (hr) |
| ES (1) | ES2632553T3 (hr) |
| HR (1) | HRP20171048T1 (hr) |
| HU (1) | HUE035167T2 (hr) |
| LT (1) | LT2643342T (hr) |
| NZ (1) | NZ610732A (hr) |
| PL (1) | PL2643342T3 (hr) |
| PT (1) | PT2643342T (hr) |
| RS (1) | RS56130B1 (hr) |
| SI (1) | SI2643342T1 (hr) |
| WO (1) | WO2012070936A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102013023224B1 (pt) * | 2012-09-14 | 2023-02-07 | Universidade Federal De Minas Gerais | PEPTÍDEO (ARGº)N-ANGIOTENSINA-(1-7) E COMPOSIÇÕES FARMACÊUTICAS PARA TRATAMENTO DE DOENÇAS |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| CN105873598A (zh) | 2013-07-03 | 2016-08-17 | 代表亚利桑那大学的亚利桑那校董会 | 用于治疗认知功能障碍的方法 |
| WO2016014342A2 (en) | 2014-07-21 | 2016-01-28 | Arizona Board Of Regents For The University Of Arizona | Ang-(1-7) derviative oligopeptides and methods for using and producing the same |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| JP6934814B2 (ja) * | 2014-11-19 | 2021-09-15 | ノボピクシス，インコーポレーテッド | Ａｔ２ｒ活性を調節するための組成物および方法 |
| WO2016107879A2 (en) * | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| WO2019238962A1 (en) * | 2018-06-14 | 2019-12-19 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
| CN110333302A (zh) * | 2019-06-25 | 2019-10-15 | 武汉兴华智慧医药科技有限公司 | 乙酰半胱氨酸溶液中n，n-二乙酰基羊毛硫氨酸的检测方法 |
| WO2021023698A1 (en) | 2019-08-02 | 2021-02-11 | Lanthiopep B.V | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
| KR102488519B1 (ko) * | 2020-07-22 | 2023-01-13 | 순천대학교 산학협력단 | 신규 고리형 펜타뎁시펩타이드 화합물 및 이를 유효성분으로 함유하는 상처 치유 또는 재생용 조성물 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6443695A (en) | 1987-08-07 | 1989-02-15 | Sun Tech Inc | Casing expansion joint device in excavator |
| US5240928A (en) | 1989-07-03 | 1993-08-31 | Merck & Co., Inc. | Substituted quinazolinones as angiotensin II antagonists |
| EP0409332A3 (en) | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
| US5166206A (en) | 1990-03-30 | 1992-11-24 | Merck & Co., Inc. | Substituted pyrimidines, pyrimidinones and pyridopyrimidines |
| US5091390A (en) | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
| EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| US5260285A (en) | 1990-12-07 | 1993-11-09 | Merck & Co., Inc. | Substituted imidazopyridazines as angiotensin II antagonists |
| US5250521A (en) | 1990-12-07 | 1993-10-05 | Merck & Co., Inc. | Substituted pyrazolopyrimidines as angiotensin II antagonists |
| CA2062558A1 (en) | 1991-03-08 | 1992-09-09 | Prasun K. Chakravarty | Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5252574A (en) | 1991-04-26 | 1993-10-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted thiophene or furan |
| US5198438A (en) | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| EP0668864A1 (en) | 1992-07-17 | 1995-08-30 | Merck & Co. Inc. | Substituted biphenylmethylimidazopyridines |
| US5310929A (en) | 1992-08-06 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
| US5376666A (en) | 1992-11-30 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl |
| WO1994027597A1 (en) | 1993-05-21 | 1994-12-08 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid angiotensin ii receptor antagonists |
| FR2716882B1 (fr) | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
| US5834432A (en) | 1995-06-06 | 1998-11-10 | The University Of Southern California | Use of angiotensin II Type 2 receptor agonists in tissue repair |
| JPH10203981A (ja) | 1997-01-21 | 1998-08-04 | Kureha Chem Ind Co Ltd | 心疾患改善剤 |
| WO1998033813A2 (en) | 1997-02-04 | 1998-08-06 | University Of Southern California | Method for accelerating healing of thermal injuries |
| WO1998058952A1 (en) | 1997-06-24 | 1998-12-30 | Proteus Molecular Design Limited | Angiotensin derivatives |
| CA2310852A1 (en) | 1997-11-26 | 1999-06-03 | University Of Southern California | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| AU2590399A (en) | 1998-02-09 | 1999-08-23 | Gere Dizerega | Method of promoting hepatic cell proliferation |
| AU2593599A (en) | 1998-02-09 | 1999-08-23 | University Of Southern California | Method of promoting keratinocyte proliferation |
| EP1053004A2 (en) | 1998-02-09 | 2000-11-22 | University Of Southern California | Use of angiotensin analogues for promoting erythropoiesis |
| WO1999042122A1 (en) | 1998-02-19 | 1999-08-26 | University Of Southern California | Method of promoting embryonic stem cell proliferation |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| WO1999045945A1 (en) | 1998-03-10 | 1999-09-16 | University Of Southern California | Improved radiation therapy methods |
| WO1999046285A2 (en) | 1998-03-11 | 1999-09-16 | University Of Southern California | Method of promoting production of living tissue equivalents |
| CA2324988A1 (en) | 1998-04-09 | 1999-10-21 | University Of Southern California | Methods for treatment and prevention of infections |
| ATE292976T1 (de) | 1998-05-11 | 2005-04-15 | Univ Southern California | Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung |
| JP3686335B2 (ja) | 1998-07-13 | 2005-08-24 | ユニヴァースティ オブ サザーン カリフォルニア | 骨および軟骨成長と修復を促進する方法 |
| EP1105149A1 (en) | 1998-08-13 | 2001-06-13 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
| JP2002533390A (ja) | 1998-12-23 | 2002-10-08 | ノバルティス アクチエンゲゼルシャフト | Ａｔ−１またはａｔ−２レセプターの増加に関連する疾患の処置のための、ａｔ−１レセプターアンタゴニストまたはａｔ−２レセプターモジュレーターの使用 |
| EP1165099B1 (en) | 1999-03-23 | 2006-08-09 | University Of Southern California | Angiotensin ii and analogs thereof for limiting scar and adhesion formation |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046128A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New bicyclic angiotensin ii agonists |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| BRPI0800585B8 (pt) | 2008-02-13 | 2021-05-25 | Univ Minas Gerais | composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) |
-
2010
- 2010-11-23 EP EP10192208A patent/EP2455388A1/en not_active Ceased
-
2011
- 2011-11-22 PT PT117916361T patent/PT2643342T/pt unknown
- 2011-11-22 KR KR1020137015946A patent/KR101512916B1/ko active IP Right Grant
- 2011-11-22 CA CA2818299A patent/CA2818299C/en not_active Expired - Fee Related
- 2011-11-22 DK DK11791636.1T patent/DK2643342T3/en active
- 2011-11-22 WO PCT/NL2011/050793 patent/WO2012070936A1/en active Application Filing
- 2011-11-22 US US13/988,085 patent/US9290540B2/en not_active Expired - Fee Related
- 2011-11-22 SI SI201131228T patent/SI2643342T1/sl unknown
- 2011-11-22 RS RS20170649A patent/RS56130B1/sr unknown
- 2011-11-22 HU HUE11791636A patent/HUE035167T2/en unknown
- 2011-11-22 ES ES11791636.1T patent/ES2632553T3/es active Active
- 2011-11-22 EP EP11791636.1A patent/EP2643342B1/en active Active
- 2011-11-22 NZ NZ610732A patent/NZ610732A/en not_active IP Right Cessation
- 2011-11-22 JP JP2013540912A patent/JP5837087B2/ja not_active Expired - Fee Related
- 2011-11-22 PL PL11791636T patent/PL2643342T3/pl unknown
- 2011-11-22 LT LTEP11791636.1T patent/LT2643342T/lt unknown
- 2011-11-22 AU AU2011332397A patent/AU2011332397B2/en not_active Ceased
- 2011-11-22 CN CN201180065409.6A patent/CN103314006B/zh not_active Expired - Fee Related
-
2015
- 2015-11-04 JP JP2015216495A patent/JP2016074675A/ja active Pending
-
2016
- 2016-01-29 US US15/009,846 patent/US9707268B2/en active Active
-
2017
- 2017-06-08 US US15/617,531 patent/US10214563B2/en not_active Expired - Fee Related
- 2017-07-03 CY CY20171100699T patent/CY1119036T1/el unknown
- 2017-07-10 HR HRP20171048TT patent/HRP20171048T1/hr unknown
-
2019
- 2019-01-14 US US16/246,978 patent/US20190135867A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT2643342T (pt) | 2017-07-12 |
| CA2818299C (en) | 2018-12-04 |
| AU2011332397B2 (en) | 2015-11-05 |
| LT2643342T (lt) | 2017-09-11 |
| US20190135867A1 (en) | 2019-05-09 |
| US9290540B2 (en) | 2016-03-22 |
| EP2643342A1 (en) | 2013-10-02 |
| KR101512916B1 (ko) | 2015-04-16 |
| US9707268B2 (en) | 2017-07-18 |
| HUE035167T2 (en) | 2018-05-02 |
| CN103314006B (zh) | 2016-04-13 |
| DK2643342T3 (en) | 2017-07-24 |
| CN103314006A (zh) | 2013-09-18 |
| WO2012070936A1 (en) | 2012-05-31 |
| ES2632553T3 (es) | 2017-09-14 |
| EP2643342B1 (en) | 2017-04-12 |
| US20140094400A1 (en) | 2014-04-03 |
| US10214563B2 (en) | 2019-02-26 |
| CY1119036T1 (el) | 2018-01-10 |
| AU2011332397A1 (en) | 2013-05-02 |
| PL2643342T3 (pl) | 2017-09-29 |
| KR20130099178A (ko) | 2013-09-05 |
| RS56130B1 (sr) | 2017-10-31 |
| NZ610732A (en) | 2014-05-30 |
| US20160220632A1 (en) | 2016-08-04 |
| JP5837087B2 (ja) | 2015-12-24 |
| SI2643342T1 (sl) | 2017-08-31 |
| JP2016074675A (ja) | 2016-05-12 |
| EP2455388A1 (en) | 2012-05-23 |
| US20170283465A1 (en) | 2017-10-05 |
| CA2818299A1 (en) | 2012-05-31 |
| JP2014503506A (ja) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171048T1 (hr) | Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe | |
| EP4299118A3 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| HRP20190982T1 (hr) | Peptidi i njihova uporaba | |
| RU2020136305A (ru) | Производные gip и пути их применения | |
| ES2404052T3 (es) | Péptidos que tienen actividad farmacológica para el tratamiento de trastornos asociados con la migración celular alterada, tal como el cáncer | |
| NO20071369L (no) | Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv | |
| EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
| CA2709884C (en) | Antimicrobial compounds | |
| NZ591497A (en) | A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment | |
| HRP20140185T1 (hr) | Peptidi i njihova primjena | |
| DK1086124T3 (da) | Nye cyclosporiner | |
| JP2015509950A5 (hr) | ||
| WO2021042039A1 (en) | Synthetic antimicrobial peptides | |
| KR20120104986A (ko) | 의료용 펩티드 | |
| RU2013120135A (ru) | Глюкозозависимые инсулинотропные пептидные аналоги | |
| RU2013127402A (ru) | Композиция, содержащая пептид и ингибитор вирусной нейраминидазы | |
| DE602007002553D1 (de) | Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung | |
| US9556229B2 (en) | Modification of peptides using a bis(thioether)arylbridge approach | |
| MX2022004718A (es) | Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico. | |
| JP2013542954A5 (hr) | ||
| MX2022000889A (es) | Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico. | |
| MY147920A (en) | Antibacterial and antiviral peptides from actinomadura namibiensis | |
| JP2016513107A5 (hr) | ||
| RU2011133224A (ru) | Новые фармацевтические композиции | |
| FR2846883B1 (fr) | Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide |